Reuters -- Germany’s Merck KGaA filed for approval of its multiple sclerosis (MS) pill cladribine in the United States in a bid to bring the first oral treatment against the debilitating disease to market.
Reuters -- Germany’s Merck KGaA filed for approval of its multiple sclerosis (MS) pill cladribine in the United States in a bid to bring the first oral treatment against the debilitating disease to market.
